45 results about "Genus Lactobacillus" patented technology

Provided are a mixture of three species of Lactobacillus fermentum strain and Lactobacillus plantarum strain and use thereof. A composition according to one aspect including, as an active ingredient, a mixture of Lactobacillus fermentum strains GB102 and GB103 and Lactobacillus plantarum strain GB104; or a lysate or culture solution thereof, or an extract of the culture solution, can be usefully used for the prevention or treatment of muscle-related disorders or obesity by alleviating the decrease in grip strength induced by aging or reducing the change in intestinal microbial environment induced by aging.

The invention discloses an intestinal flora delivery system based on a lactobacillus biological membrane and a preparation method of the intestinal flora delivery system, the intestinal flora delivery system is based on the lactobacillus biological membrane, and the biological membrane particularly refers to a biological membrane system which is induced by lactobacillus spp. Through optimized culture conditions and is mature in structure. And after physical collection and mild homogenization treatment, a biological membrane fragment suspension mainly composed of an extracellular polymeric matrix is obtained. According to the invention, a treated lactobacillus biofilm matrix is used as a core carrier, and a compact natural three-dimensional network structure can provide an excellent physical barrier; meanwhile, the biological matrix has chemical buffering potential and good biocompatibility.

The present invention relates to novel strains of Lactobacillus genus having extended shelf life properties, i.e., capable of extending the shelf life of food products (e.g., fermented milk products) at room temperature without severely impairing the antimicrobial, antifungal and / or anti-yeast effect ability of said strains when added to such products. According to another aspect, the present invention relates to an antimicrobial, antifungal or anti-yeast composition. According to yet another aspect, the present invention relates to a food product. According to another aspect, the present invention relates to a method for manufacturing a food product. According to another aspect, the present invention relates to the use of Lactobacillus strains for providing antifungal, antimicrobial and / or anti-yeast effects, for example in fermented milk products.

An object is to provide a joint function-improving composition which is useful for prevention or treatment of various arthropathies such as osteoarthritis including knee osteoarthritis as a typical example and rheumatoid arthritis because the composition has an action of promoting growth of chondrocytes and an action of suppressing the production of an inflammation factor, a cartilage matrix degradation factor, a pain factor or a neuronal outgrowth factor by synoviocytes and to provide a joint function-improving product containing the composition such as a food or a drink, feed and a medicine. A joint function-improving composition containing bacterial cells and / or a culture of a bacterium belonging to genera Lactobacillus, Lactococcus, Streptococcus or Bifidobacterium and a joint function-improving agent, a joint function-improving food or drink, a joint function-improving nutritional composition, joint function-improving feed or a joint function-improving pharmaceutical agent which is characterized by containing the joint function-improving composition.

This invention relates to the fields of microbial genetic engineering and brewing technology, and provides a PDC1 gene mutant strain resistant to 2-phenylethanol and its application in the brewing of wheat-aroma baijiu. The mutant strain is *Saccharomyces cerevisiae* PDC1_473 (HM 03), with the preservation number CCTCC M20252996. The PDC1 gene of this strain has a base mutation from T to C at position 473. When this mutant strain is applied to the solid-state fermentation of wheat-aroma baijiu, it becomes the absolutely dominant fungal community, significantly altering the microbial community structure of the fermentation system, inhibiting the growth of various conditionally pathogenic and spoilage bacteria, strengthening the fermentation environment centered on *Lactobacillus*, and significantly enhancing the rose, citrus, grassy, ​​fatty, and caramel aromas of the baijiu. It imparts a pleasant, rich ester aroma and complex aroma to the baijiu, increasing its fullness, and has broad application potential in the brewing of wheat-aroma baijiu.

The invention provides polygonatum kingianum hepta-oligosaccharide and application thereof.Fermented polygonatum kingianum is prepared through fermentation of pediococcus ethanolidurans, fermented polygonatum kingianum polysaccharide is extracted from the fermented polygonatum kingianum, and the brand-new polygonatum kingianum hepta-oligosaccharide is obtained through extraction and purification, and the structural formula of the polygonatum kingianum hepta-oligosaccharide is alpha-D-Glcp-1-(2-beta-D-Fruf-1) 5-2-beta-D-Fruf. The probiotic can be selectively utilized by intestinal microbiota at cecum and colon parts, the relative abundance of beneficial intestinal microbiota is specifically increased, the proliferation of enterococcus and lactobacillus is remarkably promoted, the pH value of colon can be reduced, the intestinal microecological balance is optimized, the biosynthesis of short-chain fatty acid is stimulated, and the probiotic has an excellent prebiotic effect and a wide application prospect.

The present invention is related to at least one isolated bacterial strain selected from at least one of the species selected from the group comprising or, alternatively, consisting of: i) Lactobacillus plantarum, ii) Lactobacillus acidophilus, and iii) Lactobacillus crispatus, or mixtures of said at least one isolated bacterial strain thereof, for use in a method of metals gut microbial bioremediation. Preferably, said metals involved in the gut microbial bioremediation are heavy metals, which are selected from the group comprising or, alternatively, consisting of Ag, Be, Ba, Cd, Cr, Mn, Hg, Pb, Cu, V, and As preferably from Cd, Cr, Hg, and Pb; or Al, or mixtures thereof. In particular, said at least one isolated bacterial strain belonging to the specie i) Lactobacillus plantarum is selected from the group comprising or, alternatively, consisting of Lactiplantibacillus plantarum 476LL 20 bi LP01 (LMG P- 21021), Lactiplantibacillus plantarum 776 / 1 bi LP02 (LMG P-21020), and Lactiplantibacillus plantarum LP14 (DSM 33401) or mixtures thereof, said at least one isolated bacterial strain belonging to the specie ii) Lactobacillus acidophilus is selected from the group comprising or, alternatively, consisting of Lactobacillus acidophilus LA02 (DSM 21717), and Lactobacillus acidophilus LA06 (DSM 23033), and said at least one isolated bacterial strain belonging to the specie iii) Lactobacillus crispatus is identified as Lactobacillus crispatus LCR04 (DSM 33487). Furthermore, the present invention regards a mixture comprising at least one isolated bacterial strain as above indicated, as well as a composition comprising said mixture, for use in a method of metals gut microbial bioremediation, wherein said metals involved in the gut microbial bioremediation are heavy metals, which are selected from the group comprising or, alternatively, consisting of Ag, Be, Ba, Cd, Cr, Mn, Hg, Pb, Cu, V, and As preferably from Cd, Cr, Hg, and Pb; or Al, or mixtures thereof and in the prevention and or reduction of the harmful effects of heavy metals on gut health.

The present invention relates to novel strains of Lactobacillus genus having extended shelf life properties, i.e., capable of extending the shelf life of food products (e.g., fermented milk products) at room temperature without severely impairing the antimicrobial, antifungal and / or anti-yeast effect ability of said strains when added to such products. The invention also relates to methods of producing such novel strains, in particular to methods of producing such novel strains via adaptive evolution.

The present invention relates to orally administered postbiotic compositions, and discloses orally administered postbiotic compositions used for the treatment of solid tumors in patients, particularly colon cancer and / or lung cancer. The compositions comprise lysates of probiotic microorganisms belonging to the genera Bacillus, Bifidobacterium, Lactobacillus, Saccharomyces, and Streptococcus.

The subject of the application is a dietary supplement containing 2.5 - 7 wt.% indole-3-carbinol, 2 - 6 wt.% epigallocatechin gallate, 30 - 70 wt.% myo-inositol, 6 - 12.5 wt.% N-acetylcysteine, 2.5 - 7 wt.% quercetin, 5 - 8.5 wt.% Omega-3 acid, 5 - 8.5 wt.% alphalipoic acid, 2 - 6 wt.% vitamin C, 1 - 5 wt.% resveratrol, 0.01 - 0.2 wt.% vitamin D3, 0.5 - 3.5 wt.% vitamin E, 0.2 - 15 wt.% alpha-lactalbumin, 0.04 - 20 wt.% curcumin, 0.2 – 15% w / w D-chiroinositol, 0.2- 24% w / w inulin, a probiotic consisting of a mixture of strains of the Lactobacillus, Bifidobacterium and Saccharomyces genera for patients with reproductive system diseases supporting the reduction of estrogen levels and estrogen and progesterone receptors.

The present invention provides histamine H1 receptor antagonism-based uses for various uses (histamine H1 receptor antagonism uses, uses to improve sleep quality and / or modulate balance of the autonomic nervous system, and uses to improve sleep quality and / or modulate balance of the autonomic nervous system. And a use for preventing the onset of autonomic nervous system dysfunction or a symptom caused thereby or for improving autonomic nervous system dysfunction or a symptom caused thereby). The present invention relates to: a composition comprising, as an active ingredient, at least one substance selected from the group consisting of indole-3-lactic acid, alpha-Asp-Phe, Val-Arg, Asp-Gly-Glu, and salts thereof, or a lactic acid bacteria culture supernatant (not containing lactic acid bacteria cells) of a lactic acid bacteria belonging to any genus selected from the group consisting of the genus Lactobacillus, the genus Lactobacillus, and the genus Lactobacillus; the liquid supernatant contains at least one substance selected from the group consisting of indole-3-lactic acid, alpha-Asp-Phe, Val-Arg, Asp-Gly-Glu, and salts thereof. The liquid supernatant contains at least one substance selected from the group consisting of indole-3-lactic acid, alpha-Asp-Phe, Val-Arg, Asp-Gly-Glu.

The present invention pertains to a method for producing an antimicrobial composition preferably comprising piceol. Moreover, the invention relates to an antimicrobial composition comprising or consisting of piceol, preferably in an excess amount compared to picein, further plant-derived substances and optionally picein. The invention further relates to a cosmetic, personal care, household, home care, pet care or pharmaceutical product comprising said antimicrobial composition. Moreover, the invention relates to the use of a microorganism, preferably a lactobacillus species, for producing an antimicrobial composition comprising piceol from a composition, preferably a plant-extract, comprising picein. In addition, the invention relates to the use of shikimic acid for increasing the antimicrobial efficacy of piceol and / or to the use of piceol for increasing the antimicrobial efficacy of shikimic acid. Further embodiments and aspects of the invention are presented in the attached claims as well as in the description and examples below.

A microbiome modulating composition and a method for producing the microbiome modulating composition are described herein. The method comprises preparing a culture from at least two of any Lactobacillus spp. bacteria, Limosilactobacillus spp. bacteria, or combinations thereof, passaging the culture on a glycogen carbon source to form a postbiotic ferment of the at least two of any Lactobacillus spp. bacteria, Limosilactobacillus spp. bacteria, or combinations thereof, and adding the postbiotic ferment to a carrier. Further disclosed is a method for treating microbial dysbiosis of an urogenital area or a skin area of a user, the method comprising applying the microbiome modulating composition to an urogenital or a skin area of a user. The disclosed methods and microbiome modulating compositions help promote the growth of healthy Lactobacillus spp. bacteria to prevent dysbiosis and other related conditions and infections.

To find out a useful living body-regulating function in a treated product of Abelmoschus manihot and to provide a functional use thereof.SOLUTION: An intestinal environment-improving agent comprising a processed product of Abutilon striata as an active ingredient, wherein the intestinal environment-improving agent increases bacteria of the genus Lactobacillusmurinus and / or the genus Parabacteroides.SELECTED DRAWING: Figure 5

This invention relates to an orally administrated nutritional supplement for the management of symptoms of irritable bowel syndrome (IBS) and related functional disorders. The composition includes:1) zinc-L-carnosine 60-100 mg per daily dose or an equivalent combination of zinc and L-carnosine providing 16?20 mg elemental Zn and 55-60 mg L-carnosine; 2) extract of Boswellia serrata resin with 25-35% total AKBA yielding 60-90 mg AKBA; 3) a probiotic blend 30-100 billion CFU that includes, at least, one strain from the genera Streptococcus, Bifidobacterium, and Lactobacillus. The active ingredients are incorporated into an acid-resistant or slow-release pharmaceutical form which limits their release in gastric pH and releases them when the pH is "greater than or equal to" 5.5, ensuring their integrity until they reach the intestine. The combination of the three above components strengthens the intestinal barrier, reduces intestinal inflammation, and restores the intestinal microbiota, providing comprehensive support to patients with IBS and related functional intestinal disorders.

The application discloses Slackia a new application of sp.D-G6, and particularly relates to Slackia application of sp.D-G6 bacterial powder in pig breeding, and belongs to the field of agricultural animal breeding and microbial technology. The bacterial strain has been preserved in the Guangdong Microbial Culture Collection Center on May 8, 2019, and the preservation number is GDMCC NO: 60661. Research shows that the bacterial powder has no obvious adverse effect on pigs, has good feeding safety, can promote pig feeding and weight gain, improve average daily feed intake and average daily weight gain, and improve growth performance. Further, the bacterial powder can regulate the microbial composition of the ileum of growing pigs, increase the abundance of Firmicutes and Lactobacillus, Lactobacillus and reduce the abundance of Proteobacteria and / or Escherichia-Shigella, Escherichia-Shigella and has application prospect of being developed into a new green feed additive.

The present invention pertains to a method for producing an antimicrobial composition preferably comprising piceol. Moreover, the invention relates to an antimicrobial composition comprising or consisting of piceol, preferably in an excess amount compared to picein, further plant-derived substances and optionally picein. The invention further relates to a cosmetic, personal care, household, home care, pet care or pharmaceutical product comprising said antimicrobial composition. Moreover, the invention relates to the use of a microorganism, preferably a lactobacillus species, for producing an antimicrobial composition comprising piceol from a composition, preferably a plant-extract, comprising picein. In addition, the invention relates to the use of shikimic acid for increasing the antimicrobial efficacy of piceol and / or to the use of piceol for increasing the antimicrobial efficacy of shikimic acid. Further embodiments and aspects of the invention are presented in the attached claims as well as in the description and examples below.

The application discloses a lactobacillus buchneri and application thereof in plant growth promotion, and belongs to the technical field of microorganisms. Through 16S rRNA sequence analysis, the lactobacillus buchneri HAC1b23.7 isolated is identified as a lactobacillus, and the preservation number is CGMCC No. 28790. The fermentation liquor of the lactobacillus buchneri HAC1b23.7 strain has a broad-spectrum promoting effect on the planting and growth of crops, and can also enhance the transformation and absorption of nutrients in soil by plants. The lactobacillus buchneri HAC1b23.7 can be prepared into a microbial preparation and applied to the field of plant growth promotion, and has a wide prospect.

The present invention relates to a non-antibiotic antimicrobial composition, new uses and methods of medical treatment or prophylaxis. In particular, the present invention relates to a non-antibiotic antimicrobial composition comprising a zeolite and at least one member of the Lactobacilli genus for the treatment of a disease or a condition associated with or caused by Helicobacter spp such as Helicobacter pylori.

The invention belongs to the technical field of microbial fermentation engineering, and particularly relates to a method for increasing the yield of extracellular vesicles of lactobacillus bacteria. The method comprises the following steps: adding galactooligosaccharide into a lactobacillus selective culture medium, inoculating lactobacillus bacteria, and culturing; separating and purifying the cultured bacterial liquid to obtain extracellular vesicles; wherein the concentration of the galactooligosaccharide in the lactobacillus selective culture medium is 30 g / L-50 g / L. According to the invention, galactooligosaccharide is added in the culture of lactobacillus johnsonii, so that the production of extracellular vesicles of lactobacillus johnsonii can be effectively improved. The method can be used for industrial mass production of the lactobacillus johnsonii extracellular vesicles, and has important value in the field of production of the lactobacillus johnsonii extracellular vesicles.

The disclosure relates to compositions and methods of using bacteria, e.g., bacteria from the genus Lactobacillus, to impart tooth enamel whitening and / or stain prevention and reduction and oral care compositions for use in such methods. The disclosure also relates to methods of using oral care compositions, methods of screening, and methods of manufacture.

An expression cassette for expression in Lactobacillus includes a promoter operatively linked to a nucleic acid encoding a protein to be expressed, the promoter being substantially identical to the PtlpA promoter.

The composition for suppressing a decrease in acquired immune function according to the present invention contains, as an active ingredient, a lactic acid bacterium product derived from a lactic acid bacterium belonging to the genus Lactobacillus. The composition for suppressing a decrease in acquired immune function suppresses a decrease in acquired immune function caused by the use of an anti-influenza drug. In addition, the lactic acid bacteria belonging to the genus Lactobacillus are preferably bulgaricus. The lactic acid bacteria of the genus Lactobacillus are, for example, German Lactobacillus subsp. Bulgaricus. In addition, the production method according to the present invention is a method for producing a composition for suppressing a decrease in acquired immune function, which is for suppressing a decrease in acquired immune function due to the use of an anti-influenza drug, by supplying a milk raw material to a lactic acid bacterium belonging to the genus Lactobacillus.

The present invention relates to specific uses of lactose-positive Streptococcus thermophilus strains in cheese production. The strains used in accordance with the present invention can carry one or more mutations in the glcK gene encoding a glucokinase, which mutations induce a reduction in glucokinase activity, carry mutations in the ccpA gene, and / or carry mutations in at least one of the genes encoding a mannose-glucose specific PTS protein. The invention further relates to compositions comprising a strain of the invention used according to the invention in combination with at least one strain of Lactobacillus and / or one strain of Mesophilic Lactobacillus, methods for making cheese, and cheese obtained by these methods.

The invention provides a preparation method of fermented polygonatum kingianum polysaccharide and polygonatum kingianum hepta-oligosaccharide, which comprises the following steps: preparing fermented polygonatum kingianum by virtue of fermentation of pediococcus ethanolidurans, extracting the fermented polygonatum kingianum polysaccharide, and extracting and purifying the fermented polygonatum kingianum polysaccharide to obtain brand-new polygonatum kingianum hepta-oligosaccharide with the structural formula of alpha-D-Glcp-1-(2-beta-D-Fruf-1) 5-2-beta-D-Fruf, the enterococcus faecium has excellent tolerance to an upper digestive tract environment, can be selectively utilized by intestinal microflora at cecum and colon parts, specifically increases relative abundance of beneficial intestinal flora, remarkably promotes proliferation of enterococcus and lactobacillus, also can reduce the pH value of colon, optimizes intestinal microecological balance, stimulates biosynthesis of short-chain fatty acid, and has a good application prospect. The prebiotic tea has an excellent prebiotic effect and a wide application prospect.

Vegan protein powder, characterized in that the protein powder contains at least rice protein, pea protein, a prebiotic, an amino acid, a probiotic of the genus Bifidobacterium and a probiotic of the genus Lactobacillus, wherein the vegan protein powder is free of sweeteners.

The use of a human milk oligosaccharide in the preparation of a food product which contributes to the regulation of the intestinal flora of a mother and her offspring via ingestion by the mother. The human milk oligosaccharide is 2'-fucosyllactose. The mother is in the period of pregnancy and / or nursing. The contribution to the regulation of the intestinal flora of the offspring comprises at least one of increasing the relative abundance of Lactobacillus HT002 in the intestinal tract of the offspring, increasing the relative abundance of Akkermansia in the intestinal tract of the offspring, increasing the relative abundance of Clostridia_UCG-014_unclassified in the intestinal tract of the offspring, and increasing the relative abundance of Bacteroides in the intestinal tract of the offspring.

The present invention relates to compositions comprising microorganisms for use in the reduction of blood urate concentration. These compositions can be used for the therapeutic and the preventive treatment of subjects at risk or suffering from elevated blood urate levels. The compositions can be pharmaceutical compositions or nutraceutical composition 5 that are used for treatment and prevention of urate and hyperuricemia associated diseases such as cardiovascular disease, metabolic syndrome, non-alcoholic fatty liver disease, chronic kidney disease, gout, insulin resistance, hypertension, dyslipidaemia, renal insufficiency, obesity, pre-diabetes and diabetes.

The present disclosure relates to a postbiotic composition that delivers a mixture or blend of postbiotic components in combination with micronutrients, said postbiotic components derived from beneficial bacteria from Lactiplantibacillus spp. or Lactobacillus spp. (L. plantarum, L. acidophilus, and L. rhamnosus). The postbiotic compositions of the disclosure may either be a live organism capable of proliferation in the subject, a non-living strain such as, but not limited to, a heat-killed proliferative strain, or a combination thereof. In addition to the postbiotic derived from Lactiplantibacillus or Lactobacillus beneficial bacterial strains, the compositions include micronutrients such as Vitamin D, vitamin B12, and herbal extracts in various combinations to ameliorate gut and metabolic health of a human subject.